Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 12/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809539 | 0.98 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL828730 | 0.98 | OPRM1 (0.61) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL15202950 | 0.89 | OPRM1 (0.55) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL15202972 | 0.89 | OPRM1 (0.55) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL4418077 | 0.89 | OPRM1 (0.55) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL2554375 | 0.87 | OPRM1 (0.69) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL10063412 | 0.86 | OPRL1 (0.77) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 | |
| SCHEMBL13243418 | 0.85 | OPRM1 (0.68) | OPRM1OPRK1OPRL1 | |
| SCHEMBL1238158 | 0.84 | OPRM1 (0.62) | OPRM1OPRK1OPRL1 | |
| SCHEMBL28667548 | 0.83 | OPRM1 (0.80) | OPRM1OPRK1OPRL1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793596-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190241610-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-10138270-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20160362450-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9359399-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150197545-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2015-07-16 | — | — | US | disclosed |
| US-8951970-B2 | Synthetic peptide amides for pain | CARA THERAPEUTICS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8486894-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130012448-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2064228-B1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8217007-B1 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7727963-B2 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7713937-B2 | Synthetic peptide amides and dimeric forms thereof | CARA THERAPEUTICS, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | CARA THERAPEUTICS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-2064228-A2 | SYNTHETIC PEPTIDE AMIDES | Cara Therapeutics, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7402564-B1 | Synthetic peptide amides | CARA THERAPEUTICS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| WO-2008057608-A2 | SYNTHETIC PEPTIDE AMIDES | CARA THERAPEUTICS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138270-B2 | Synthetic peptide amides | VIP, OPRK1, OPRL1 | OPRM1 7/4885OPRK1 2/4885OPRL1 3/4885 |
| US-20150197545-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | OPRM1 7/4885OPRK1 2/4885OPRL1 3/4885 |
| US-20190241610-A1 | SYNTHETIC PEPTIDE AMIDES | OPRK1, OPRL1, OPRD1 | OPRM1 4/4885OPRK1 1/4885OPRL1 2/4885 |
| US-20100075910-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRK1 1/4885OPRL1 4/4885 |
| US-20090156508-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885OPRK1 1/4885OPRL1 3/4885 |
| US-20110118186-A1 | SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885OPRK1 1/4885OPRL1 3/4885 |
| US-20090075907-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | OPRM1 7/4885OPRK1 2/4885OPRL1 3/4885 |
| US-20160362450-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | OPRM1 7/4885OPRK1 2/4885OPRL1 3/4885 |
| US-20130012448-A1 | SYNTHETIC PEPTIDE AMIDES | VIP, OPRK1, OPRL1 | OPRM1 7/4885OPRK1 2/4885OPRL1 3/4885 |
| US-10793596-B2 | Synthetic peptide amides | OPRK1, OPRL1, OPRD1 | OPRM1 4/4885OPRK1 1/4885OPRL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.